| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Department of Pathology, Tel-Aviv University Medical School, and Chaim Sheba Medical Center, Tel-Aviv [J. L., M. W., G. D.], and Israel Institute for Biological Research, Ness Ziona [Y. S.], Israel
Levan was shown to inhibit lymphoma development in AKR mice. Growth of tumor was inhibited at the site of injection and in metastases. Levan caused a decrease in the incidence of tumors, and it reduced pleomorphism, mitoses, and invasiveness of tumors in comparison to nonlevanized mice. Evidence of tumor cell destruction was observed in levanized mice. The effect of levan on tumor development was dose dependent.
1 Supported in part by a grant from the Israel Cancer Society and by a Student Grant from the California Foundation for Biochemical Research.
2 Established Investigator of the Chief Scientist's Bureau, Ministry of Health, Israel. To whom requests for reprints should be addressed, at the Chaim Sheba Medical Center, Tel-Hashomer, Israel.
Received 12/ 5/74. Accepted 4/14/75.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |